HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21

Benzinga · 1d ago
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.